Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2002-12-04
2009-08-25
Andres, Janet L (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S277400
Reexamination Certificate
active
07579365
ABSTRACT:
The invention relates to the use of N-substituted indole-3-glyoxylamides of the general formula I as antitumor agentsand to a pharmaceutical composition having antitumor action, characterized in that it contains at least one of the compounds of the general formula 1, if appropriate also in the form of the physiologically tolerable acid addition salts or N-oxides. Furthermore, the invention also includes antitumor agents comprising as active compound one or more N-substituted indole-3-glyoxylamides according to the general formula 1 and, if appropriate, their physiologically tolerable acid addition salts and, if possible, N-oxides and a pharmaceutically utilizable carrier and/or diluent or auxiliary substance in the form of tablets, coated tablets, capsules, solutions for infusion or ampoules, suppositories, patches, powder preparations which can be employed by inhalation, suspensions, creams and ointments.
REFERENCES:
patent: 5405864 (1995-04-01), Broka et al.
patent: 6008231 (1999-12-01), Lebaut et al.
patent: 6225329 (2001-05-01), Richter et al.
patent: 6232327 (2001-05-01), Nickel et al.
patent: 6251923 (2001-06-01), Hofgen et al.
patent: 6262044 (2001-07-01), Moller et al.
patent: 6344467 (2002-02-01), Lebaut et al.
patent: 6432987 (2002-08-01), Gunther et al.
patent: 6693119 (2004-02-01), Nickel et al.
patent: 7452910 (2008-11-01), Nickel et al.
patent: 2004/0171668 (2004-09-01), Nickel et al.
patent: 2004/0266762 (2004-12-01), Gerlach
patent: 2006/0040991 (2006-02-01), Roessler
patent: 2006/0280787 (2006-12-01), Roessler et al.
patent: 2008/0027110 (2008-01-01), Nickel et al.
patent: 2008/0057124 (2008-03-01), Nickel et al.
patent: 2315989 (1973-04-01), None
patent: 19636150 (1998-03-01), None
patent: 2000239252 (2000-09-01), None
patent: 98/09946 (1998-03-01), None
patent: 9809946 (1998-03-01), None
patent: WO 98/09946 (1998-03-01), None
patent: WO-99/46237 (1999-09-01), None
patent: WO-99/51224 (1999-10-01), None
patent: WO-99/55696 (1999-11-01), None
patent: WO-00/67802 (2000-11-01), None
Podwinski et. al., “Synthesis of some 5-benzyloxyindole-3-glyoxylic acid amides”, CA 70:37598, p. 327, vol. 60, 1969.
Lipp et. al., “Some derivatives o 5-benzyloxy-3-indolylglyoxylic acid”, CA 52:18374, p. 1958, vol. 52.
Ooi VE, Liu F., Curr. Med. Chem. Jul. 7, 2000(7): 715-29, NCBI abstract.
Ca 103:205123, Fiszer-Maliszewska.
Fiszer-Maliswewska , “Chemotherapy and immunity”, edited by Gerhard Pulverer, 1985; 13(): 215-230.
Copending U.S. Appl. No. 11/894,591.
Copending U.S. Appl. No. 11/894,729.
Hcaplus Abstract 1985: 605123, Document No. 103: 205123 Abstract, Fiszer-Maliszewska et. al., (1985).
Caplus 1969:37598; Podwinski Bohdan, Synthesis of some 5-benzul . . . , RN #21421-40.9.
Caplus AN 1999:708761, Hofgen Norbert et al, RN 247584-34-5.
Gura, Trisha, “Cancer Models: Systems for Identifying New Drugs Are Often Faulty,” Science, 278(5340):1041-1042 (1997).
Johnson et al., British J. of Cancer, 84(10):1424-1431 (2001).
Bacher, G., et al., “D-24851, a Novel Synthetic Microtubule Inhibitor, Exerts Curative Antitumoral Activity in Vivo, Shows Efficacy toward Multidrug-resistant Tumor Cells, and Lacks Neurotoxicity,” Cancer Research, 61(1):392-399 (2001).
Evans, S.M., et al., “Probing the 5-HT3Receptor Site Using Novel Indole-3-Glyoxylic Acid Derivatives,” Med. Chem. Res., 3:386-406 (1993).
Guenther, E.G., et al., “Discovery and Synthesis of Novel N-substituted Indoly-3-glyoxylic Acid Derivatives With Tubulin-binding Activity as Anti-Cancer Agents,” Proceedings of the American Association for Cancer Research Annual Meeting, 41:769 (2000).
Raab, G., et al., “ZIO-301 (Indibulin) a Novel Tubulin Polymerization Inhibitor Has Potent Anti-tumor Activity and a Distinct Tubulin Binding Site,” Proceedings of the American Association for Cancer Research Annual Meeting, 48:337 (2007).
Dupont et al., “Antiangiogenic properties of a novel shark cartilage extract: potential role in the treatment of psoriasis,” J. Cutan. Med. Surg., 2:146-152 (1998) (Abstract).
Brune Kay
Emig Peter
Günther Eckhard
Le Baut Guillaume
Nickel Bernd
Andres Janet L
Robinson Binta M
Ropes & Gray LLP
ZIOPHRAM Oncology, Inc.
LandOfFree
Indolyl-3-glyoxylic acid derivatives having antitumor action does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Indolyl-3-glyoxylic acid derivatives having antitumor action, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Indolyl-3-glyoxylic acid derivatives having antitumor action will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4065423